REMUS Remus Pharma. Q4 FY25 results (Jan–Mar 2025) and concall
Remus Pharmaceuticals reported strong consolidated financial performance for FY25, with significant revenue and EBITDA growth driven by the full consolidation of its US subsidiary. The company is strategically expanding its international presence, focusing on higher-margin B2C business, and advancing its product pipeline, including new molecules like semaglutide. Management anticipates sustainable growth and margin expansion in the coming years, supported by R&D and new product launches.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY25: revenue up 64.0%, net profit up 175.0% against the same quarter last year.
| Line item | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|
| Revenue | 20 | 25 | 29 | 36 | 38 +90% | 41 +64% |
| EBITDA | 5 | 6 | 9 | 12 | 11 +120% | 15 +150% |
| Net profit | 4 | 4 | 8 | 9 | 9 +125% | 11 +175% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
